EA201270416A1 - Моноклональные антитела - Google Patents

Моноклональные антитела

Info

Publication number
EA201270416A1
EA201270416A1 EA201270416A EA201270416A EA201270416A1 EA 201270416 A1 EA201270416 A1 EA 201270416A1 EA 201270416 A EA201270416 A EA 201270416A EA 201270416 A EA201270416 A EA 201270416A EA 201270416 A1 EA201270416 A1 EA 201270416A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fibrinogen
fibrin
domain
inhibits
моноклональные
Prior art date
Application number
EA201270416A
Other languages
English (en)
Other versions
EA023477B1 (ru
Inventor
Катерина Акассоглу
Original Assignee
Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния filed Critical Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния
Publication of EA201270416A1 publication Critical patent/EA201270416A1/ru
Publication of EA023477B1 publication Critical patent/EA023477B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Изобретение предлагает выделенное антитело, связывающее домен γC фибрина или фибриногена. В различных вариантах осуществления этого изобретения такое антитело ингибирует адгезию микрокглий к домену γC фибрина или фибриногена, ингибирует связывание рецептора Mac-1 с доменом γC фибрина или фибриногена, и/или ингибирует клинические симптомы экспериментального аутоиммунного энцефаломиелита. Предлагаются также различные способы использования антител, фармацевтических композиций, наборов, векторов, клеток, содержащих векторы, и способы получения антител.
EA201270416A 2009-10-02 2010-09-30 МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, СВЯЗЫВАЮЩЕЕ ДОМЕН γ-С ФИБРИНА ИЛИ ФИБРИНОГЕНА EA023477B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24801409P 2009-10-02 2009-10-02
PCT/US2010/050873 WO2011041518A1 (en) 2009-10-02 2010-09-30 Monoclonal antibodies

Publications (2)

Publication Number Publication Date
EA201270416A1 true EA201270416A1 (ru) 2012-08-30
EA023477B1 EA023477B1 (ru) 2016-06-30

Family

ID=43826649

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270416A EA023477B1 (ru) 2009-10-02 2010-09-30 МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, СВЯЗЫВАЮЩЕЕ ДОМЕН γ-С ФИБРИНА ИЛИ ФИБРИНОГЕНА

Country Status (38)

Country Link
US (1) US8877195B2 (ru)
EP (1) EP2483416B1 (ru)
JP (1) JP5883389B2 (ru)
KR (1) KR101793221B1 (ru)
CN (1) CN102575277B (ru)
AR (1) AR078490A1 (ru)
AU (1) AU2010300559B2 (ru)
BR (1) BR112012008370B8 (ru)
CA (1) CA2774256C (ru)
CL (1) CL2012000788A1 (ru)
CO (1) CO6440561A2 (ru)
CR (1) CR20120127A (ru)
CY (1) CY1118540T1 (ru)
DK (1) DK2483416T3 (ru)
DO (1) DOP2012000089A (ru)
EA (1) EA023477B1 (ru)
ES (1) ES2614939T3 (ru)
GE (2) GEP20156214B (ru)
GT (1) GT201200096A (ru)
HK (1) HK1168871A1 (ru)
HR (1) HRP20170110T1 (ru)
HU (1) HUE031571T2 (ru)
IL (1) IL218621B (ru)
IN (1) IN2012DN03154A (ru)
LT (1) LT2483416T (ru)
MA (1) MA33704B1 (ru)
MX (1) MX2012003811A (ru)
MY (1) MY159359A (ru)
NZ (1) NZ598770A (ru)
PL (1) PL2483416T3 (ru)
PT (1) PT2483416T (ru)
SI (1) SI2483416T1 (ru)
SM (1) SMT201700083B (ru)
TN (1) TN2012000149A1 (ru)
TW (1) TWI511741B (ru)
UA (1) UA108860C2 (ru)
WO (1) WO2011041518A1 (ru)
ZA (1) ZA201202227B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
AU2013271378A1 (en) 2012-06-07 2014-12-18 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
CN105283196B (zh) * 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 用于产生和使用构象-特异性抗体的方法和组合物
EP3091996B1 (en) * 2014-01-11 2024-04-10 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compositions and methods for in vitro assays of fibrin activity
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
WO2016145186A1 (en) 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
SG11201910113PA (en) * 2017-05-02 2019-11-28 Nat Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
CN115461462A (zh) * 2020-03-31 2022-12-09 国立研究开发法人国立癌症研究中心 与纤维蛋白结合的抗体及含有该抗体的药物组合物
WO2022133028A1 (en) * 2020-12-16 2022-06-23 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Use of fibrin-targeting immunotherapy to reduce coronavirus pathogenesis
WO2022159776A1 (en) * 2021-01-21 2022-07-28 Therini Bio, Inc. Antibodies which bind human fibrin and methods of use
CA3222880A1 (en) * 2021-06-18 2022-12-22 Jeffrey Stavenhagen Antibodies which bind human fibrin or fibrinogen ?c domain and methods of use
AU2022293581A1 (en) * 2021-06-18 2024-01-25 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
WO2024044583A1 (en) * 2022-08-22 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Human anti-fibrin antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031675A1 (en) * 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CN102212132A (zh) * 2004-05-27 2011-10-12 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
US7807645B2 (en) * 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment

Also Published As

Publication number Publication date
AR078490A1 (es) 2011-11-09
EP2483416B1 (en) 2016-11-23
IN2012DN03154A (ru) 2015-09-18
CN102575277B (zh) 2015-07-29
KR101793221B1 (ko) 2017-11-02
BR112012008370B1 (pt) 2020-12-22
IL218621B (en) 2018-07-31
CY1118540T1 (el) 2017-07-12
IL218621A0 (en) 2012-05-31
CL2012000788A1 (es) 2012-09-14
EP2483416A4 (en) 2013-06-26
CN102575277A (zh) 2012-07-11
JP5883389B2 (ja) 2016-03-15
DK2483416T3 (en) 2017-02-20
PT2483416T (pt) 2017-02-14
MA33704B1 (fr) 2012-10-01
ES2614939T3 (es) 2017-06-02
SI2483416T1 (sl) 2017-06-30
DOP2012000089A (es) 2012-06-30
HRP20170110T1 (hr) 2017-03-24
UA108860C2 (xx) 2015-06-25
MX2012003811A (es) 2012-05-08
AU2010300559B2 (en) 2014-11-27
MY159359A (en) 2016-12-30
KR20120094924A (ko) 2012-08-27
CA2774256C (en) 2019-02-19
CR20120127A (es) 2012-05-28
NZ598770A (en) 2014-01-31
LT2483416T (lt) 2017-04-25
JP2013506425A (ja) 2013-02-28
GT201200096A (es) 2014-12-23
GEP20156214B (en) 2015-01-12
US8877195B2 (en) 2014-11-04
GEP20166458B (en) 2016-04-11
HUE031571T2 (en) 2017-07-28
ZA201202227B (en) 2014-11-26
EA023477B1 (ru) 2016-06-30
EP2483416A1 (en) 2012-08-08
BR112012008370B8 (pt) 2021-05-25
WO2011041518A1 (en) 2011-04-07
SMT201700083B (it) 2017-03-08
CA2774256A1 (en) 2011-04-07
BR112012008370A2 (pt) 2016-11-29
TWI511741B (zh) 2015-12-11
PL2483416T3 (pl) 2017-05-31
US20120183560A1 (en) 2012-07-19
AU2010300559A1 (en) 2012-04-05
HK1168871A1 (zh) 2013-01-11
TW201116298A (en) 2011-05-16
CO6440561A2 (es) 2012-05-15
TN2012000149A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
EA201270416A1 (ru) Моноклональные антитела
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
MX2012012927A (es) Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
TR201910213T4 (tr) Disülfürle stabilize edilmiş çok değerlikli antikorlar.
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
CL2008003561A1 (es) Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias.
EA200800812A1 (ru) Композиции антитела против cd3
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
MX345092B (es) Anticuerpos anti-tau humanos,.
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
MA34004B1 (fr) Protéines de liaison à cd127
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
WO2010031749A9 (en) Compositions and methods for detecting tlr3
WO2009139853A3 (en) Human monoclonal antibodies against human chemokine receptor ccr7
WO2008109533A3 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
WO2009051672A3 (en) Natural killer immunoglobulin-like receptor (kir) assay
ATE539152T1 (de) Neue verfahren
WO2009108307A3 (en) Diagnostic uses of anti-h8 monoclonal antibodies
TH132228B (th) โมโนโคลนอล แอนติบอดี (Monoclonal anitbody)
TW200718711A (en) Polypeptides that bind BR3 and uses thereof